Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO for thrombocytopenia after high-dose cytarabine consolidation in AML
ChiCTR2100049137Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human thrombopoietin in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Days of platelet < 20×10^9/L. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100049137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049137.